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Abstract
Background: The coronavirus pandemic (Covid-19) presents a variety of challenges for ongoing clinical trials,
including an inevitably higher rate of missing outcome data, with new and non-standard reasons for missingness.
International drug trial guidelines recommend trialists review plans for handling missing data in the conduct and
statistical analysis, but clear recommendations are lacking.
Methods: We present a four-step strategy for handling missing outcome data in the analysis of randomised trials
that are ongoing during a pandemic. We consider handling missing data arising due to (i) participant infection, (ii)
treatment disruptions and (iii) loss to follow-up. We consider both settings where treatment effects for a ‘pandemic-
free world’ and ‘world including a pandemic’ are of interest.
Results: In any trial, investigators should; (1) Clarify the treatment estimand of interest with respect to the occurrence
of the pandemic; (2) Establish what data are missing for the chosen estimand; (3) Perform primary analysis under the
most plausible missing data assumptions followed by; (4) Sensitivity analysis under alternative plausible assumptions.
To obtain an estimate of the treatment effect in a ‘pandemic-free world’, participant data that are clinically affected by
the pandemic (directly due to infection or indirectly via treatment disruptions) are not relevant and can be set to
missing. For primary analysis, a missing-at-random assumption that conditions on all observed data that are expected
to be associated with both the outcome and missingness may be most plausible. For the treatment effect in the ‘world
including a pandemic’, all participant data is relevant and should be included in the analysis. For primary analysis, a
missing-at-random assumption – potentially incorporating a pandemic time-period indicator and participant infection
status – or a missing-not-at-random assumption with a poorer response may be most relevant, depending on the
setting. In all scenarios, sensitivity analysis under credible missing-not-at-random assumptions should be used to
evaluate the robustness of results. We highlight controlled multiple imputation as an accessible tool for conducting
sensitivity analyses.
Conclusions: Missing data problems will be exacerbated for trials active during the Covid-19 pandemic. This four-step
strategy will facilitate clear thinking about the appropriate analysis for relevant questions of interest.
Keywords: Missing data, Pandemic, Coronavirus SARS-CoV-2, Covid-19, Randomised trials, Estimands, Sensitivity
analysis, Controlled multiple imputation
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Background
On 11th March 2020 the World Health Organisation de-
clared the novel coronavirus (SARS-CoV-2) outbreak as a
pandemic (Covid-19) [1]. Covid-19 presents a variety of
challenges for the conduct and analysis of ongoing clinical
trials. This has been recognised by the FDA, EMA and
MHRA, who have issued guidance on trial conduct during
Covid-19 [2–4]. Subject to participant and investigator
safety, it is recommended that data collection continue for
as long as possible, but where feasible this is to be under-
taken remotely. Difficulties in adhering to protocol de-
fined follow-up are nonetheless inevitable, and will result
in an extra ‘chunk’ of missing outcome data occurring for
different reasons than would occur without the pandemic.
As well as physically missing data, there will be additional
concern for participants providing data during Covid-19
when their outcomes are influenced by it. In this situation,
a central consideration is the treatment effect to be ob-
tained from the trial (estimand), as this may sometimes re-
quire treating some of the collected data as missing. It is
therefore recommended that trial statisticians review and
update protocol plans for handling missing data in the
analysis [2, 3].
Missing data are a critical issue for the analysis of tri-
als, since any statistical method implicitly makes an as-
sumption about the distribution of the unobserved data,
and it is not possible to verify this assumption without
the missing data. If the assumption is wrong, both the
treatment effect estimate and associated estimate of pre-
cision will generally be biased. This could have damaging
clinical implications. When the proportion of missing
data is small, the bias may be negligible, but the larger
the proportion, the greater the concern for the scientific
credibility of the trial. Nevertheless, the principles
underlying the handling of missing data in the analysis
remain unchanged: the primary analysis should be con-
ducted under the most plausible assumption as to why
the data are missing and their associated distribution,
followed by sensitivity analyses under alternative plaus-
ible assumptions for the missing data distribution to as-
sess the robustness of conclusions [5–9]. However, the
considerations for which missing data assumptions
might be most appropriate may differ for trials active
during a pandemic. In this article we present a four-step
strategy for handling missing outcome data in the ana-
lysis of clinical trials whose conduct overlap a pandemic
period. The guidance is intended to help statisticians
and investigators to maintain the scientific integrity of
ongoing trials, despite an unexpected pandemic.
Methods
We developed a four-step strategy for handling missing
outcome data in the analysis of trials whose conduct
overlap a pandemic period. The strategy can be used
regardless of the outcome type, but our examples will
focus on continuous outcomes. This framework was de-
veloped to be consistent with the statistical principles
outlined in the ICH-E9 guidelines [10] and ICH-E9(R1)
addendum on estimands and sensitivity analysis in clin-
ical trials [11]. A particular focus is on carrying out rele-
vant primary and sensitivity analyses to ensure trial
results address the question of interest, and are unbiased
under plausible assumptions about the missing data.
Using Rubin’s classification of missing mechanisms [12],
we provide structured guidance to help assist decisions
about handling missing data under plausible assump-
tions. Following an outline of the main issues raised by a
pandemic we describe each point of the guidance in
turn, which we illustrate using the ASCOT trial, an oph-
thalmic trial ongoing during Covid-19. We summarise
the guidance using a decision tree.
The ASCOT trial
As an example, we consider the Adjunctive Steroid
Combination in Ocular Trauma (ASCOT) trial, a prag-
matic, double-blind, multi-centre randomised controlled
trial testing whether adjunctive steroid (triamcinolone
acetonide), given at the time of surgery for open globe
trauma can improve the outcome of surgery [13]. Adults
undergoing vitrectomy for open globe trauma were ran-
domised to receive adjunctive intraocular and periocular
steroid or standard treatment (no steroid) during surgery
in a 1:1 ratio. The primary outcome is improvement in
visual acuity, measured using the ETDRS (number of let-
ters read at 4 m and 1m) in clinic at 6 months. An in-
terim ETDRS measure is recorded at 3 months. ASCOT
had completed recruitment and treatment for all partici-
pants, but had approximately 10% of participants in
follow-up when it was interrupted by the Covid-19
pandemic.
Results
A four-step strategy for handling missing outcome data
in the context of a pandemic
Our proposed strategy consists of four key steps, sum-
marised in Fig. 1. We now discuss each point in turn.
Step 1: clarify the treatment estimand of interest with
respect to the occurrence of the pandemic
In any trial, to help ensure the trial answers the question
of interest it is important to precisely define the treat-
ment estimand. The term estimand describes the con-
ceptual quantity that we wish to estimate numerically
from a trial. The ICH E9(R1) addendum [11] describes
five key attributes that form the description of an esti-
mand. These are: (A) The population; the patients
targeted by the scientific question, (B) The treatment
condition of interest and the alternative treatment
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condition(s) e.g. control or placebo, (C) The variables
(or endpoint) to be obtained for each patient required to
address the scientific question, (D) The specification of
how to account for intercurrent events to reflect the sci-
entific question of interest, (E) The population level
summary for the variable which provides a basis for a
comparison between treatment conditions. For trials on-
going during a pandemic, in line with ICH-E9 [11], we
assume a defined treatment estimand prior to the occur-
rence of the pandemic. Clarification on whether the pan-
demic impacts the trial estimand is first required. This
will inform the missing data problem (step 2) and subse-
quent handling of missing data (steps 3 and 4).
A pandemic will not typically change estimand attri-
butes A, B, C and E, although there will be exceptions
[14, 15]. It is most likely to introduce a number of new
intercurrent (post-randomisation) events, which are de-
fined as events affecting the interpretation or existence
of trial outcomes [6, 11, 14]. A pandemic may directly
affect participant outcomes if they become infected with
the underlying disease (e.g. infection with Covid-19).
Conversely, a pandemic may indirectly affect participant
outcomes due to treatment and standard care disrup-
tions or participant behaviour changes (e.g. due to in-
creased health care demands or participant health care
anxieties).
We consider two estimands that may be of interest.
The first is the treatment effect in a hypothetical ‘pan-
demic-free world’, where interest lies in the treatment
effect we would have seen had the pandemic not hap-
pened. For this estimand, the impacts of the pandemic
on the trial (e.g. infection of trial participants, treatment
interruptions, etc), whether direct or indirect, obscure
our interpretation of the relevant outcome data. As such,
this estimand uses a hypothetical strategy to deal with
these intercurrent events, where interest lies in the treat-
ment effect that would be seen had these events not
occurred.
The second estimand is the treatment effect in a
‘world including a pandemic’, where interest lies in the
treatment effect that occurs in the presence of the pan-
demic. Here, the effects of the pandemic (e.g. infection
of trial participants, treatment interruptions, etc) are dir-
ectly relevant to the estimand. As such, this estimand
uses a treatment policy approach to deal with these
intercurrent events. We note that this estimand depends
both on the degree to which the trial overlapped with
the pandemic, and the severity of the pandemic during
the overlap period.
For instance, if the same trial were to have started on
a different date (and therefore, have a different amount
of overlap with the pandemic), the value of the ‘world
including a pandemic’ estimand may be quite different
for the trial. As such, the generalisability of this estimand
should be carefully considered.
The most appropriate estimand of interest will be trial
specific and should be guided by the question of key
clinical interest [14, 15]. For many trials there may be
more than one estimand of interest. As outlined in ICH-
E9(R1), following primary analysis, alternative estimands
targeting different clinical questions of interest may be
explored in supplementary analyses [11]. The following
guidance in this four-step strategy can be similarly ap-
plied to such supplementary analyses.
After clarifying which estimand is of interest for the
analysis at hand (‘world including a pandemic’ vs. ‘pan-
demic- free world’ estimand), the challenges of a pan-
demic then surround handing the additional unplanned
intercurrent events in a way that remains consistent with
the estimand. Some of these pandemic-related intercur-
rent events may mean that some recorded participant
outcomes are no longer relevant for the chosen
estimand.
Step 2: establish what data are missing for the chosen
estimand
We can only begin to think about missing data in any
trial setting once the treatment estimand has been de-
fined: only once we know exactly what we are aiming to
estimate can we know whether we have the data re-
quired to estimate it. We define missing data as data that
are required to estimate the estimand of interest, but
that are unavailable. Some data maybe be physically
Fig. 1 Strategy for handling missing outcome data in clinical trials
during a pandemic
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missing (i.e. not collected) or some observed data may
be best treated as missing in the analysis (i.e. set missing
by the analyst) if not relevant for the estimand of
interest.
For the ‘pandemic-free world’ estimand only partici-
pant data that was unaffected by pandemic-related inter-
current events is required for the analysis (i.e. data
collected before or after the pandemic, and data col-
lected during the pandemic which was not impacted by
pandemic-related infection, treatment interruptions,
etc). For such an estimand, if any data are collected from
participants who experience pandemic-related intercur-
rent events (directly or indirectly affecting their out-
comes), the affected data are not needed in the analysis
and so may be best set missing; including affected par-
ticipant data will adversely impact the desired estimate.
Clinical input will be required to establish how to iden-
tify pandemic-related intercurrent events. It has been
discussed elsewhere how a pragmatic definition of the
pandemic start and end dates (e.g. based on national or
local Covid-19 case numbers) may be used to under-
stand the pandemic effect on participant outcomes [15].
Additional data will most likely need to be collected to
determine whether participants experienced any pan-
demic related intercurrent events, for example such as
Covid-19 infection, reason for treatment interruption
(pandemic related or not). EMA guidelines [3] highlight
the importance of capturing deviations resulting from
the Covid-19 pandemic, and related reasons, to help dis-
tinguish between data affected and unaffected by the
pandemic. Pragmatic, uniform, trial specific decisions
may be required. We recommend trialists are transpar-
ent in reporting all criteria used to inform the analysis.
Here, any data unobserved or set missing due to the
pandemic creates a missing data problem in the analysis.
There may also be missing data from participants whose
outcomes were planned to be collected during the pan-
demic, were not directly or indirectly clinically impacted
by the pandemic, but were unobserved due to changes
in follow-up procedures or participant engagement.
Alongside this, there is the ‘usual’ missing data from par-
ticipant’s pre- and/or post-pandemic. All such missing
data must be handled in line with the targeted ‘pan-
demic-free world’ estimand.
For the ‘world including a pandemic’ estimand, all par-
ticipant data pre-, during- and post-pandemic will be re-
quired for analysis. However, any participant data not
collected still creates a missing data problem that must
be addressed in line with the targeted ‘world including a
pandemic’ estimand.
We note that if data that are affected by the pandemic,
(i.e data from participants who experience a pandemic-
related intercurrent event through infection, or treat-
ment interruption, etc) are included in an analysis, then
the estimated treatment effect will correspond to a
‘world including a pandemic’ estimand. If this is not de-
sired, and the ‘pandemic-free world’ estimand is re-
quired, observed data that are clinically affected by the
pandemic in any way (directly or indirectly) should be
set to missing. In settings where the pandemic doesn’t
clinically affect any participant outcomes (directly or in-
directly) the two estimands will coincide and the distinc-
tion is not relevant.
Step 3: perform primary analysis under the most
plausible missing data assumptions
Once data that are missing have been established, the
most appropriate missing data assumptions can be de-
fined for the primary analysis. The analysis can then be
performed using a statistical method that provides un-
biased estimation under the chosen assumption. We
now review the three general classes of missing data
assumptions before providing suggestions on aspects to
consider when forming assumptions for missing data in
the context of trials impacted by a pandemic.
Missing data assumptions (or mechanisms) can be cate-
gorised into three broad types [12]: Missing-completely-
at-random (MCAR), Missing-at-random (MAR) and
Missing-not-at-random (MNAR). Participant data are
MCAR when the reason for the missingness is completely
unrelated to the participants’ unobserved outcome or ob-
served values of other recorded variables; the distribution
of the missing participant data will look no different to
that of the observed participant data. Data are MAR when
missingness does not depend on participants unobserved
data values once we have taken into account the informa-
tion in their observed data in the analysis, such as baseline
characteristics or, in longitudinal settings, earlier re-
sponses. Only once the observed data is conditioned on,
will the missing data distribution then look no different to
the observed data distribution. In trials, typically MAR will
be more likely than MCAR; particularly in longitudinal
studies, where conditioning on the partially observed lon-
gitudinal outcome data will make the MAR assumption
much more plausible. Finally, data are MNAR when the
missingness remains dependent on the unobserved values
of the data in some form (or on observed data not in-
cluded in the analysis); the missing participant data will
have a potentially substantively different distribution to
the observed data. Table 1 summarises the principal
methods of analysis for unbiased estimation of a treatment
effect (the estimand) under MCAR, MAR and MNAR in
clinical trials (not an exhaustive list of options, see [7] or
[8] for more detailed guidance).
The most appropriate assumptions for missing data in
the primary analysis will be trial and estimand specific.
For all trials where follow-up continues in person, and
resources allow, we recommend trialists attempt to
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contact participants who do not provide follow-up to de-
termine why they are missing data e.g. to identify
whether they were directly or indirectly impacted by the
pandemic and how this has affected their outcome. This
will help inform the most appropriate missing data as-
sumptions. For trials ongoing during a pandemic differ-
ent missing data assumptions may be best for different
groups of participants to ensure assumptions align with
the underlying estimand of interest, and we explore this
further below.
While there are no assumptions that can be universally
recommended, we now provide some structured guid-
ance to help assist the decision on plausible missing data
assumptions, if the trial includes:
(i) Participants directly clinically affected by a
pandemic (e.g. Covid-19 infection),
(ii) Participants indirectly clinically affected by a
pandemic (e.g. changes to treatment/standard
care),
Table 1 Methods for unbiased analysis under MCAR/MAR/MNAR in clinical trials (not an exhaustive listing of options)
Assumption Method for unbiased estimation Comments
MCAR Any complete case analysis Easy to implement but may not use all the available information in
the data. Excludes participants with any missing data.
MAR Complete case analysis incorporating all variables associated with
both outcome and missingness
Easy to implement but may not use all the available information in
the data. Excludes participants with any missing data. Generally
cannot incorporate post-randomisation data.
Mixed model incorporating all variables associated with both
outcome and missingness, which may include post-randomisation
variables (e.g. for a longitudinal trial a mixed model for repeated
measured MMRM)
Earlier response data can be incorporated in the analysis to
strengthen/justify MAR. Includes all observed data on each
participant. Additional post-randomisation data predictive of both
missingness and outcome that are required to be included to jus-
tify MAR, but that the treatment estimate (estimand) should not be
conditioned on can also be included, however careful model speci-
fication is required to do so (e.g. any post-randomisation variables
must be included as additional responses in the model with separ-
ate means for each treatment group, for detailed guidance see [7]).
Multiple Imputation incorporating all variables associated with
both outcome and missingness, which may include post-
randomisation variables
Closely approximates a complete case/mixed model analysis when
the variables included in the imputation and analysis model match
those in the complete case/mixed model analysis. The imputation
model must include as a minimum all variables included with the
analysis model [16]. Provides a convenient analysis method when
conditioning on particular variables is required to justify/strengthen
a MAR assumption, but conditioning on these in the analysis is not
required/appropriate. This is because variables that are predictive of
both outcome and missingness, but that the treatment effect
(estimand) should not be adjusted by, can be included in the
imputation model and not in the subsequent analysis model.
MNAR Selection models: Consists of a model for the outcome data and a
model for the occurrence of missing data
For example, may consist of a logistic model to model the log
odds of response and how this depends on the unobserved
outcome. Expert/clinical knowledge is required to inform how the
log odds of response depends on the unobserved outcome. Can
be fitted using maximum likelihood, or within a Bayesian
framework [8].
Pattern mixture models: Consists of a model for the outcome data
for each missing data pattern
Expert/clinical knowledge is required to inform how the outcome
data distribution varies for each missing data pattern. Can be fitted
using maximum likelihood, within a Bayesian framework or,
implemented in a multiple imputation framework, when it is
referred to as ‘Controlled Multiple Imputation’ [8, 15]:
Controlled Multiple Imputation: Combines pattern mixture
modelling and multiple imputation (e.g. delta-based or reference-
based Multiple Imputation)
Data is imputed multiple times from a pattern mixture model. The
analyst has direct ‘control’ over the imputation distribution. For
example, in delta-based imputation a numerical offset term, delta,
is typically added to the expected value of the missing data to as-
sess the impact of unobserved participants having a worse or bet-
ter response than of those observed. Reference-based imputation
draws imputed values with some reference to the observed data in
other groups of the trial, typically in other treatment arms. Different
MNAR assumptions can be made for different groups of individuals
in the same trial analysis by postulating different distributions for
imputation or MAR and MNAR assumptions may be made for dif-
ferent groups [17].
For any trial analysis, care should be taken to ensure an appropriate method is chosen than handles all missing data appropriately for the treatment estimand
of interest
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(iii)Participants lost to follow-up during pandemic
times (outcomes unaffected by pandemic),
(iv) Participants lost to follow-up during non-pandemic
times (e.g. pre or post-pandemic).
We address these first for the ‘pandemic-free world’
estimand, followed by the ‘world including a pandemic’
estimand, considering the ASCOT trial as an example. A
decision tree summarising our guidance, placed within
the ICH E9(R1) framework for aligning trial objectives
with conduct and analysis, [10], is provided in Fig. 2 for
trialists to follow to support the selection of appropriate
missing data assumptions.
‘Pandemic- free world’ estimand
Participants directly and indirectly clinically affected by a
pandemic (i) and (ii)
Outcome data that are clinically affected by a pandemic
either directly (e.g. via participant infection with Covid-
19), or indirectly, are treated as missing for the ‘pan-
demic-free world’ estimand and can be handled in the
same way as each other. For such data, an MAR assump-
tion —conditional on randomised treatment arm and all
observed variables expected to be associated with both
the trial outcome and being missing (i.e. being directly
or indirectly affected) — may be the most reasonable as-
sumption for the primary analysis. Predictors of both
missingness and outcome could include baseline partici-
pant characteristics (e.g. in ASCOT baseline vision, sex,
comorbidities) and/or earlier observed data under pre-
pandemic times (e.g. 3 month vision) or during−/post-
pandemic times provided these are not affected by
pandemic-related intercurrent events. This will assume
the missing outcomes for those affected would have
been similar to those of participants observed pre- pan-
demic (and if relevant those observed during or post the
pandemic era, who did not experience any pandemic-
related intercurrent events and are therefore not affected
by the pandemic in any way) with the same values of the
observed data, thus enabling estimation of the treatment
effect in a pandemic free world.
If it is not required to estimate the treatment estimand
conditionally on one or more of the observed variables
that are related to both outcome and missingness, for
example if a comorbidity was expected to be related to
both, analysis options (not exhaustive) include using
either (a) a carefully constructed mixed model [7, 8] or
(b) multiple imputation where the comorbidity can be
included in the imputation model and not the analysis
model [7, 8, 16].
Participants lost to follow-up during pandemic times (iii)
Follow-up may continue for participants whose trials
outcomes are not impacted directly or indirectly during
a pandemic (remotely or in person), but only some of
their outcomes may be observed. Here, relative to non-
pandemic times, there may be different factors that are
expected to be associated with both outcome being
missing (due to pandemic follow-up interruptions) and
the trial outcome to consider to justify an MAR assump-
tion. These factors may differ depending on the precise
mode of follow-up during the pandemic.
For example, for ASCOT participants not infected by
the pandemic (assuming the pandemic has no other in-
direct impacts on participants 6 month vision) if in-
person follow-up continues, age may become an import-
ant factor to incorporate in the MAR assumption as
strongly related to outcome: while prior to the pan-
demic, age was not associated with both missingness
and outcome (only with the outcome, 6 month vision),
due to the pandemic older participants may become
more likely to stay at home to avoid increased risks of
infection. The dataset may consequently end up having a
higher rate of missing older people (who are unaffected
by the pandemic, but have poorer vision simply because
of age) compared to younger people (who are unaffected
by the pandemic and may have better vision simply be-
cause of age).
In some special cases there may be no observed
participant data during the pandemic because follow-
up stops for everyone. This might occur when all trial
participant outcomes would be impacted (directly or
indirectly) by the pandemic. Or, follow-up may stop
for all — regardless of any impacts on trial outcomes
— for practical/logistical reasons (e.g. clinical staff re-
deployed). As the halting of follow-up impacts all par-
ticipants equally, there will likely be no pandemic-
specific factors associated with both missingness and
outcome (relative to pre-pandemic times) to incorpor-
ate for participants lost to follow-up during the pan-
demic for the ‘pandemic-free world’ estimand. Here
MAR conditional on predictors of outcome and miss-
ingness expected in non-pandemic times would likely
be the most appropriate assumption. Where follow-up
stops for all participants, unobserved data during this
period could alternatively be considered MCAR, but
this would only be reasonable in the absence of any
time trends within the participant data. In some trial
settings there may be underlying time trends, for ex-
ample, due to seasonal diseases (winter deaths, infec-
tious diseases etc) or changing severity of disease
recruited (as trial teams become more confident) that
will create a MAR mechanism. Since the absence of
such time trends is a fairly strong assumption, where
follow-up stops for all participants, we generally rec-
ommend performing analysis under a MAR assump-
tion, conditional on predictors of outcome and
missingness expected in non-pandemic time.
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Participants lost to follow-up during non-pandemic times
(iv)
In ASCOT, and likely in any trial overlapping the pan-
demic, there will inevitably also be data missing from
participants in non-pandemic times. Trialists should
consider whether the same missing data assumption is
relevant for data missing pre- (or post-) pandemic and
during the pandemic.
Where prior to the pandemic, a reduced set of factors
related to outcome and missingness were considered ap-
propriate for analysis under MAR (e.g., in ASCOT, treat-
ment arm, baseline vision and 3month vision), analysis
under MAR including an enlarged set of factors (to also
handle participants of type (i), (ii) and/or (iii), e.g. also
including sex, comorbidities and/or age) is suggested.
Alternatively, multiple imputation could proceed separ-
ately for the two groups (not affected and affected by the
pandemic) or for individuals with missing data of type
(i), (ii), (iii) and (iv).
In summary, for the ‘pandemic-free world estimand’ a
carefully constructed enlarged MAR assumption (includ-
ing all observed data expected to be related to both
missingness and outcome across the trial participants)
will often be most appropriate for primary analysis.
‘World including a pandemic’ estimand
In a world including a pandemic, participant outcomes
that are clinically affected by the pandemic (i. directly
with the disease or ii. indirectly via changes to treat-
ment/standard care) may either be observed – or ex-
pected – to be quite different to those observable under
non-pandemic circumstances. To estimate the ‘world in-
cluding a pandemic’ estimand, assumptions must be
made for any participant data not collected during the
pandemic era in a manner consistent to what would
have been seen in the pandemic world; similarly, pre
−/post-pandemic missing data must also be handled in a
manner consistent with pre−/post- pandemic times. We
now provide some suggestions on aspects to consider
when forming missing data assumptions for this
estimand.
Participants directly clinically affected by a pandemic (i)
Analysis under MAR, including an indicator of direct
pandemic impact e.g. Covid-19 infection status, and all
observed data expected to be associated with both trial
outcome and missingness (e.g. treatment, risk factors for
being impacted by Covid-19 and the vision outcome
such as age or diabetes), may be most relevant for the
Fig. 2 Decision tree to support the appropriate handling of missing outcome data in clinical trials during a pandemic
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data of participants directly impacted in primary analysis
– provided, given the observed factors, the distribution
of the unobserved outcome values will be the same as
for those observed and directly impacted.
If there are, however, no observed outcome data from
directly impacted participants, or if it is not anticipated
that Covid-19 infection status will allow adequate mod-
elling of the distribution of the missing outcomes for
other Covid-19 infected participants then a MNAR as-
sumption may be more appropriate for the data of par-
ticipants directly impacted. A strong justification must
accompany any MNAR assumption. It is most likely that
a direct pandemic impact, i.e. Covid-19 infection, will
have a negative impact on the trial outcome of interest,
though the reverse is of course possible. As a worst case
scenario, one could assume that all infected participants
behaved like those observed in the trial’s standard care/
control arm, to reflect no treatment benefit (e.g. a jump-
to-reference assumption) [18]. Or for the infected partic-
ipants, one could assume a worse outcome than ob-
served for those in their treatment arm by a particular
quantity. For example, in ASCOT, suppose Covid-19 in-
fection negatively impacts vision in a way that is not
captured by any observed participant characteristics, we
could assume any unobserved infected participant has
an outcome 20% worse than for those observed (under
MAR) in their treatment arm. A discussion between cli-
nicians, researchers on the ground interacting with the
Covid-19 infected participants and statisticians should
occur to ensure appropriate, justifiable, MNAR assump-
tions are chosen.
Participants indirectly affected by a pandemic (ii)
Analysis under MAR given the pandemic time period
(e.g. during/pre−/post-) and observed variables antici-
pated to be associated with both the trial outcome and
missingness may be most relevant in primary analysis
for the data of participants indirectly impacted. If indir-
ect impacts fluctuate over the pandemic period (e.g. the
standard of care over a pandemic period changes over
time due to fluctuating health care demands) there may
be more than just one time point factor to incorporate
in the missing data assumptions.
Where a trial data set also includes observed data from
participants who are directly impacted by the pandemic,
and outcome values of those directly and indirectly af-
fected are impacted in different ways, it may also be rele-
vant to include infection status within the missing data
assumption.
If there are no observed outcome data from indirectly
impacted participants, or if there are no observed vari-
ables that along with the pandemic time point can be
used to fully model the outcome distribution for indir-
ectly affected participants with missing data, an MNAR
assumption may be more appropriate for the data of
participants indirectly impacted by a pandemic. Careful
thought would need to be given as to what the missing
outcomes might have looked like in the pandemic world
and a thorough justification should be provided along-
side any employed MNAR assumption.
Participants lost to follow-up during pandemic times (iii)
For the data of participants whose outcomes are not dir-
ectly or indirectly impacted by the pandemic, but who
have missing data during the pandemic (e.g. participants
in ASCOT who decide not to attend the 6 month
follow-up during Covid-19 to avoid travel and risk of in-
fection) analysis under MAR given observed data antici-
pated to be related to both outcome and missingness
may be most relevant; which may differ depending on
the precise mode of follow-up during the pandemic.
Where the trial data set also includes observed partici-
pant data that are directly and/or indirectly clinically af-
fected by the pandemic it will be essential to also
include infection status and/or pandemic time period
(pre/during/post) within the missing data assumption
for primary analysis for the data of participants impacted
by outcome interruptions only (i.e. for those lost to
follow-up during the pandemic). This will ensure the
missing data for the non-affected participants is mod-
elled based upon the observed non-affected participants
(and not the observed clinically affected participants).
Participants lost to follow-up during non-pandemic times
(iv)
Trialists should consider whether the same missing data
assumption is relevant for data missing pre- (or post-)
pandemic due to loss to follow-up. Analysis under MAR
including an enlarged set of factors (to also handle par-
ticipants with types (i), (ii) and/or (iii), e.g. also including
diabetes, age, infection status, pandemic time point as
relevant) may be suitable to handle loss to follow-up
outside pandemic times.
Of note, participant characteristics might in some
cases be related to both outcome and missingness in the
during and non-pandemic time periods, but in different
ways. If this is an issue we recommend incorporating in-
teractions between time periods (during/pre/post pan-
demic) and the affected characteristics in any missing
data assumption. Similarly, in some settings participant
characteristics might be related to both outcome and
missingness but in different ways for those directly in-
fected by the pandemic versus those not. If so trialists
should consider incorporating interactions between in-
fection status and the corresponding participant charac-
teristics in the missing data assumption.
In summary, for the ‘world including a pandemic’ esti-
mand a carefully constructed enlarged MAR assumption,
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involving all observed data expected to be related to
both missingness and outcome across the trial partici-
pants, potentially including pandemic time period (pre/
during/post) and/or participant pandemic infection sta-
tus where relevant is likely to be the most appropriate
starting point for primary analysis. In some cases, an
MNAR assumption may be more appropriate for partici-
pant data that are directly or indirectly clinically affected
by the pandemic, however strong justification of the
chosen MNAR assumption would be required. In the
next section, we highlight an accessible method for ana-
lysis when different missing data assumptions are re-
quired for different participants in the same trial
analysis.
Of course, a pandemic’s clinical impact (direct or in-
direct) may be unknown for all or some participants in
some trials. Where it is unknown for all participants
(e.g. Covid-19 infection status not collected) it will not
be possible to condition the missingness on Covid-19 in-
fection status, but the pandemic time period (pre/dur-
ing/post) can still be incorporated when targeting the
‘world including a pandemic’ estimand.
Analysis when different missing data assumptions are
required for different participants
One method which enables analysis under a variety of
missing data assumptions is Controlled Multiple Imput-
ation (MI) [17, 19]. Controlled MI means the analyst ex-
erts direct ‘control’ over the imputation distribution.
Unobserved data are then imputed under the specified
distribution multiple times to obtain multiple complete
data sets. These are each analysed with the analysis
model of interest that would have been used in the ab-
sence of missing data. Results are then combined across
imputed data sets (using Rubin’s rules [20]) to provide a
single treatment estimate which appropriately takes into
account all the uncertainty associated with the unseen
values, given the postulated distribution.
We discussed above how different missing data as-
sumptions may sometimes be required for different indi-
viduals in the same trial analysis. Controlled multiple
imputation provides an accessible tool for this. Different
distributions for the missing data of different groups of
individuals (e.g. MAR and MNAR) can be postulated for
data imputation. For analysis under MNAR, to assess
the impact of unobserved participants having a worse or
better response than those observed, missing participant
data can be imputed assuming the distribution of the
observed data (i.e. MAR distribution) +/− a specified nu-
merical location shift. This is known as delta-based mul-
tiple imputation. Alternatively missing participant data
may be drawn from a distribution that is formed with
some reference to observed data in other groups of the
trial, typically in other treatment arms. This is known as
reference based multiple imputation [18]. For example,
in a two-arm placebo-controlled trial, participants with
missing data in the active arm can be imputed to follow
the distribution of the placebo arm, assuming no treat-
ment benefit following drop-out (referred to as a jump-
to-reference imputation). Delta and reference based mul-
tiple imputation methods can been implemented with
continuous [7, 17, 18], binary [21, 22], ordinal [23],
count [24–26] and survival data [27–30].
An accessible tutorial provides a more detailed prac-
tical overview of controlled MI procedures, with worked
examples and Stata code, where different assumptions
are incorporated in one analysis [17].
Controlled multiple imputation also provides an ac-
cessible, flexible tool for contextually relevant sensitivity
analysis which is the next and final key step when hand-
ling missing outcome data during a pandemic. We have
previously shown that the aforementioned controlled
procedures (delta- and reference-based multiple imput-
ation) provide valid inference, as the proportion of infor-
mation lost due to missing data under MAR is
approximately preserved in the analysis [31]; That is in-
formation anchored inference will be obtained.
Step 4: perform sensitivity analysis under alternative
plausible assumptions
Any missing data assumption is unverifiable, so sensitiv-
ity analyses under alternative plausible missing data as-
sumptions should be conducted, regardless of the type
of missing data assumption employed for primary ana-
lysis. Sensitivity analysis should address the same ques-
tion as the primary analysis [32]. If it can be shown that
the inference is robust to different missing data assump-
tions then this will provide confidence in the conclu-
sions despite the missing data. If conclusions vary in
sensitivity analysis it is equally important to demonstrate
under what conditions results look different to ensure
misleading conclusions are not drawn. As described
above, a MAR assumption will be most plausible for pri-
mary analysis in the majority of scenarios. However
MAR is still a strong unverifiable assumption. For both
the ‘pandemic- free world’ and ‘world including a pan-
demic’ estimand it will be important to conduct sensitiv-
ity analyses under alternative plausible MNAR
assumptions, which have MAR as a departure point and
align with the chosen estimand.
The challenge is that there will be numerous ways in
which the unobserved data could be modelled, so where
should one start? One option is to use the MAR distri-
bution as a departure point. The MAR data distribution
provides an unambiguous starting point for MNAR ex-
ploration. For example, starting with the specification of
the conditional data distribution implied by MAR, one
can perform sensitivity analysis exploring departures
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from MAR by shifting the parameter values of the distri-
bution in a contextually relevant manner for the chosen
estimand. As introduced above, an analysis under such
an assumption can be accessibly conducted using ‘delta-
method’ multiple imputation.
For the ‘pandemic free world’ estimand, it cannot be
ruled out that —in the absence of a pandemic—partici-
pants with missing data would have actually have had
worse/or better outcomes than those observed in the
trial. This is why conducting sensitivity analysis using a
series of shifts in the MAR distribution may be a par-
ticularly useful approach to demonstrate the robustness
of conclusions here.
For the ‘world including a pandemic’ estimand; depend-
ing on the underlying disease, it may be more likely that
those affected by the pandemic —or also those that decide
not to attend follow-up visits (in person or remotely) —
had poorer outcomes than those observed in pandemic
times. This MNAR scenario becomes more likely in the
context of a pandemic, as a greater number of participants
in poorer health may stay at home to avoid additional
pandemic implications. Or, depending on the trial context,
it may be healthier participants who stay at home — since
they feel they don’t have an essential need for clinical
follow-up. Starting with an appropriate MAR assumption
(conditional on factors in the pandemic time period, pan-
demic infection status and other predictors of response in
a pandemic era) one can assess alternative contextually
plausible MNAR assumptions by shifting the parameters
of this distribution. The parameter shifts should be rele-
vant to what the unobserved outcomes are hypothesised
to look like in the pandemic world.
In any trial setting, careful thought must be given to
what are appropriate values for the sensitivity analysis
parameters when utilising such an approach. Discussions
between clinicians, researchers interacting with the trial
participants (those infected and those not infected) and
statisticians should take place to help ensure appropriate
missing data assumptions are chosen and justified.
The difference between the MAR and MNAR distri-
bution can alternatively be described using within-
trial information by reference to other groups in the
data in sensitivity analysis. The parameters of the ob-
served data distribution, estimated assuming MAR,
can be mixed around, across arms rather than within,
to form contextually relevant MNAR distributions for
the unobserved data. This is referred to as ‘reference
based MI.’ Further practical guidance in implementing
such sensitivity analysis, including examples and Stata
code is provided in [17].
Discussion
We have provided a four-step strategy to facilitate the
handling of missing outcome data in trials ongoing
during a pandemic, such as Covid-19. In the first step,
the treatment estimand of interest must be clarified
(treatment effect in a ‘pandemic-free world’ or the ‘world
including a pandemic’). In step 2, the estimand will in-
form what data are missing. In step 3, primary analysis
should then be conducted under the most plausible
missing data assumption, or set of assumptions, that
align with the trial estimand, followed by sensitivity ana-
lysis in step 4, under alternative credible assumptions
that also align with the estimand.
Of course, the treatment effect in a ‘pandemic-free
world’ or the ‘world including a pandemic’ are not the
only potential estimands that may be targeted for trials
overlapping a pandemic. For example, an alternative
estimand is the treatment effect only ‘during a pan-
demic’. The most appropriate estimand choice will be
trial and context specific. We hope the guidance on as-
sumptions for missing data in this manuscript provide a
basis for considerations on other estimands.
Missing data assumptions will be trial and estimand
specific and will require careful consideration to ensure
assumptions align with the trial estimand clarified in
step 1. Multi-disciplinary discussions between statisti-
cians, clinicians, researchers on the ground interacting
with participants will be required to determine the ap-
propriate assumptions. As detailed above, analysis under
a carefully constructed MAR assumption will in many
cases be most plausible for primary analysis, provided all
observed data that are expected to be associated with
both the outcome and missingness are included. Sensi-
tivity analysis under credible MNAR assumptions is then
recommended to demonstrate the robustness or sensitiv-
ity of results across scenarios. During a pandemic,
MNAR will become more credible in most contexts. Re-
sults of sensitivity analyses should be reported alongside
the primary result, so that robustness of results can be
openly assessed.
To conduct unbiased analysis under MAR in longitu-
dinal trial settings (a) a carefully constructed mixed
model [7, 8] or (b) multiple imputation analysis can be
used (other options also exists) [7, 8, 16]. The natural
flexibility of multiple imputation means it may be a
more accessible analysis option where observed data
need to be conditioned on to justify the MAR analysis
but treatment estimates should be unadjusted for (e.g.
interim values of outcome). Using multiple imputation,
such observed data can be readily including the imput-
ation model but not the analysis model. Controlled mul-
tiple imputation, where the analyst exerts direct control
over the imputation distribution (away from MAR), pro-
vides an accessible tool for assessing the impact of a var-
iety of contextually relevant MNAR assumptions. Thus
multiple imputation may provide a unifying tool for both
primary and sensitivity analysis in the pandemic era [17].
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Naturally, if a large number of participants experience
pandemic-related intercurrent events and their data are
either unobserved or set to missing there may be con-
cerns as to whether the ‘pandemic-free world’ estimand
can be reliably estimated using any missing data method.
Trialists will need to carefully consider the available data
and the feasibility of obtaining reliable results before
conducting analysis with their chosen method of
analysis.
The focus of this guidance is on handling missing data.
However, when the ‘pandemic-free world’ estimand is of
interest and data are affected by the pandemic and ob-
served, setting the affected data to missing and employ-
ing an appropriate method to handle the arising
missingness is not the only analysis option. Instrumental
Variable (IV) methods, used previously to handle treat-
ment switching in trials, provide an alternative analysis
option [33, 34]. For example, Rank Preserving Structural
Failure Time Models (RPSFTM) for estimating counter-
factual survival times or structural nested mean models
or more traditional two-stage least squares (2SLS)
methods for other data types [35–37]. When a large pro-
portion of the observed data are affected by the pan-
demic IV methods that appropriately model the
observed data may be of value. However, regardless of
the analytical approach employed (e.g. missing data ap-
proach versus modelling observed data), when a substan-
tial majority of data are impacted by the pandemic any
analysis for the pandemic free world estimand will be
heavily assumption led. Assumptions will simply be dif-
ferent. Thus, caution will still be required when targeting
the ‘pandemic-free world’ and there is a large proportion
of affected data be this observed or set missing.
We have focused exclusively on the impact of missing
outcome data on treatment effect estimation during
Covid-19. In our discussions we did not consider an
interaction between Covid-19 initiation and the treat-
ment effect which may be relevant to the ‘world includ-
ing a pandemic’ estimand. EMA guidelines recommend
considering treatment effect estimation for the pre-, dur-
ing and post-Covid-19 periods where relevant [3]. The
methods discussed here for handling missing data will
be applicable where this interaction is included.
Finally, we note that this four-step strategy could be
readily adapted and adopted in non-pandemic settings
to handle the occurrence of other unplanned intercur-
rent events. In step 1 the treatment estimand can be
clarified with respect to any unplanned intercurrent
event and steps 2, 3, and 4 follow as specified in Fig. 1.
Conclusions
Missing data issues are likely to be exacerbated in pan-
demics. We have proposed a four-step strategy to con-
sider and think through the issues raised in a systematic
manner. More than ever, careful consideration of miss-
ing data assumptions is required. Further, because more
data are missing, sensitivity analysis will play a more cru-
cial role than ever in demonstrating the robustness or
sensitivity of trial results. Our suggestions will not cover
all potential trial settings, but the generic strategy illus-
trated, by the examples, provides a practical framework
for many trials.
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